Targeted therapies in small cell lung cancer (Review)

被引：27

作者：

Lu, Hong-Yang ^{[1
]}

Wang, Xiao-Jia ^{[1
]}

Mao, Wei-Min ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac, Hangzhou 310022, Zhejiang, Peoples R China

来源：

ONCOLOGY LETTERS | 2013年 / 5卷 / 01期

关键词：

small cell lung cancer; targeted therapy; epidermal growth factor receptor; vascular endothelial growth factor; apoptosis; gene; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; BCL-2 ANTISENSE OLIGONUCLEOTIDE; C-KIT; ADJUVANT VACCINATION; RESPONDING PATIENTS; IMATINIB MESYLATE; EGFR MUTATION; DOUBLE-BLIND; CHEMOTHERAPY;

D O I：

10.3892/ol.2012.791

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the leading cause of cancer-related mortality. Small cell lung cancer (SCLC) accounted for 12.95% of all lung cancer histological types in 2002. Despite trends toward modest improvement in survival, the outcome remains extremely poor. Chemotherapy is the cornerstone of treatment in SCLC. More than two-thirds of patients who succumb to lung cancer in the United States are over 65 years old. Elderly patients tolerate chemotherapy poorly and need novel therapeutic agents. Targeted drugs have less toxicity than chemotherapy drugs, but no targeted agents have been approved for use in the treatment of SCLC patients to date. Certain new targeted agents, including gefitinib, bevacizumab and Bcl-2 inhibitors, offer a promise of improved outcomes, however negative results are more commonly reported than positive. This review focuses on targeted therapies in SCLC.

引用

页码：3 / 11

页数：9

共 50 条

[41] Molecularly Targeted Therapies in Locally Advanced Non-Small-Cell Lung Cancer [J].

Devarakonda, Siddhartha ;

Morgensztern, Daniel ;

Govindan, Ramaswamy .

CLINICAL LUNG CANCER, 2013, 14 (05) :467-472

[42] The role of new targeted therapies in small-cell lung cancer [J].

Rossi, A ;

Maione, P ;

Colantuoni, G ;

Guerriero, C ;

Gridelli, C .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 51 (01) :45-53

[43] Targeted Therapies for Advanced Non-Small Cell Lung Cancer [J].

Starakis, Ioannis ;

Nikolakopoulos, Achilleas ;

Mazokopakis, Elias E. .

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2012, 15 (08) :641-655

[44] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC) [J].

Lange, Ansgar ;

Prenzler, Anne ;

Frank, Martin ;

Golpon, Heiko ;

Welte, Tobias ;

von der Schulenburg, J-Matthias .

BMC PULMONARY MEDICINE, 2014, 14

[45] HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies [J].

Uy, Natalie F. ;

Merkhofer, Cristina M. ;

Baik, Christina S. .

CANCERS, 2022, 14 (17)

[46] The current status of targeted therapy for non-small cell lung cancer [J].

Francis, H. ;

Solomon, B. .

INTERNAL MEDICINE JOURNAL, 2010, 40 (09) :611-618

[47] Targeted therapies in lung cancer [J].

Besse, B. ;

Ropert, S. ;

Soria, J. C. .

ANNALS OF ONCOLOGY, 2007, 18 :135-142

[48] New therapies in small cell lung cancer: A narrative review [J].

Papavasileiou, Sotirios ;

Kouvela, Marousa ;

Charpidou, Andriani .

PNEUMON, 2024, 37 (01)

[49] Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context [J].

Le, Alexander D. ;

Alzghari, Saeed K. ;

Jean, Gary W. ;

La-Beck, Ninh M. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 :223-236

[50] Determinants of Survival in Advanced Non-Small-Cell Lung Cancer in the Era of Targeted Therapies [J].

Bauml, Joshua ;

Mick, Rosemarie ;

Zhang, Yu ;

Watt, Christopher D. ;

Vachani, Anil ;

Aggarwal, Charu ;

Evans, Tracey ;

Langer, Corey .

CLINICAL LUNG CANCER, 2013, 14 (05) :581-591

← 1 2 3 4 5 →